Announcements
Sidley Represents Capricor Therapeutics in US$172.5 Million Common Stock Offering
December 10, 2025
Sidley represented Capricor Therapeutics, Inc. in connection with an underwritten public offering of 6,900,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase additional shares to cover over-allotments, bringing the total gross proceeds to Capricor from the offering to approximately US$172.5 million. Piper Sandler & Co. and Oppenheimer & Co. Inc. acted as the joint book-running managers for the offering and H.C. Wainwright & Co. acted as co-manager.
The deal team was led by Rob Carlson (M&A and Private Equity) and included Nick DeAngelis and John E. Walker (M&A and Private Equity).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private PlacementJuly 17, 2026Sidley Finishes H1 2026 Among Top Three US$1B+ Dealmakers in TexasJuly 16, 2026European Commission Signals Targeted Procedural Simplification of the Foreign Subsidies Regulation – Without Weakening EnforcementJuly 16, 2026Inspection Rights, Internal Affairs, and Personal Jurisdiction: Orchid Global’s Procedural LessonJuly 15, 2026Sidley Advises EMZ Partners on Its Significant Minority Investment in Steinbach & VollmannJuly 13, 2026Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZenecaJuly 13, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory